Drug Trial Radar · NCT04432376
Efficacy and Safety Study of Miconazole Oil Versus Vehicle on Fungal Infection of the Ear Canal (Otomycosis)
Last checked: Nov 19, 2026Latest source record: Jan 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
382
Actual
Start
Jul 8, 2020
Primary completion
Nov 1, 2021
Study completion Nov 1, 2021
Sponsor
- Lead sponsor
- Hill Dermaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Abond CRO Inc.
- First posted
- Jun 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 7 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study involves two portions, a randomized, double-blind portion and an open-label portion, to evaluate the efficacy and safety of Miconazole oil 2% versus its Vehicle in the treatment of fungal infection of the outer ear canal (Otomycosis). The subjects randomized in the first portion of the study will have active fungal infection of the ear(s) and will be treated with either Miconazole Oil or the Vehicle for 14 days twice daily, 5 drops into the affected ear(s) per dose. The subjects enrolled in the open-label portion of the study may or may not have active fungal infection of the ear(s), and will be given the Miconazole Oil active drug following the same application of 5 drops into the ear(s) twice daily for 14 days. The intention of the study is to evaluate the efficacy of Miconazole Oil on fungal infection of the ears when applied using 5 drops into the ear(s) twice daily for 14 days continuously. This study also intends to show safety of Miconazole Oil 5 drops into each ear twice a day for 14 consecutive days.
Conditions
- Otomycosis
Interventions
miconazole 2% oilDrug
Drug treatment of otomycosis for 14 days
vehicle oilDrug
Placebo treatment of otomycosis for 14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects With Therapeutic CureTime frame: 21 days from first day of drug application
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Head and Neck Surgery Specialists
Chula Vista, California
UCSD
La Jolla, California
DaVinci Research, LLC
Roseville, California
Sacramento ENT / DaVinci Research
Sacramento, California
Lake ENT & FPS
Leesburg, Florida
Advanced ENT & Allergy
Louisville, Kentucky
DelRicht Research
New Orleans, Louisiana
University of Missouri
Columbia, Missouri
OnSite Clinical Solutions
Dillon, South Carolina
Carolina ENT
Orangeburg, South Carolina
West Houston Clinical Research Services
Houston, Texas
Research Your Health
Plano, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.